case_images: PMC10880137_01
case_images: Chest CT at the onset of pneumonitis in two cases. (A) A chest CT at the onset of pneumonitis in Case 1; (B) A chest CT at the onset of pneumonitis in Case 3
case_images: cureus-0016-00000052714-i01.jpg
case_images: PMC10880137_03_cureus-0016-00000052714-i01.jpg
case_images: FIG1
case_images: After 1.8 months from treatment initiation, chest CT revealed pneumonitis and MPM progression (Figure 1B, 2E, 2F).
case_images: First CT evaluation during treatment with nivolumab plus ipilimumab. The CT scan shows a size reduction in lung cancer in the first three cases. (A) A chest CT at the start of treatment in Case 1; (B) A chest CT after 2.5 months from treatment initiation; (C) A chest CT at the start of treatment in Case 2; (D) A chest CT after 1.8 months from treatment initiation (E); A chest CT at the start of treatment in Case 3; (F) A chest CT after 1.8 months from treatment initiation.. Yellow lines indicate target lesions.
case_images: cureus-0016-00000052714-i02.jpg
case_images: PMC10880137_03_cureus-0016-00000052714-i02.jpg
case_images: FIG2
case_images: After 1.8 months from treatment initiation, chest CT revealed pneumonitis and MPM progression (Figure 1B, 2E, 2F).
case_images: PMC10880137_02
case_images: First CT evaluation during treatment with nivolumab plus ipilimumab. The CT scan shows a size reduction in lung cancer in the first three cases. (A) A chest CT at the start of treatment in Case 1; (B) A chest CT after 2.5 months from treatment initiation; (C) A chest CT at the start of treatment in Case 2; (D) A chest CT after 1.8 months from treatment initiation (E); A chest CT at the start of treatment in Case 3; (F) A chest CT after 1.8 months from treatment initiation.. Yellow lines indicate target lesions.
case_images: cureus-0016-00000052714-i02.jpg
case_images: PMC10880137_03_cureus-0016-00000052714-i02.jpg
case_images: FIG2
case_images: After 1.8 months from treatment initiation, chest CT revealed pneumonitis and MPM progression (Figure 1B, 2E, 2F).
case_images: PMC10880137_03
case_images: Chest CT at the onset of pneumonitis in two cases. (A) A chest CT at the onset of pneumonitis in Case 1; (B) A chest CT at the onset of pneumonitis in Case 3
case_images: cureus-0016-00000052714-i01.jpg
case_images: PMC10880137_03_cureus-0016-00000052714-i01.jpg
case_images: FIG1
case_images: After 1.8 months from treatment initiation, chest CT revealed pneumonitis and MPM progression (Figure 1B, 2E, 2F).
case_images: First CT evaluation during treatment with nivolumab plus ipilimumab. The CT scan shows a size reduction in lung cancer in the first three cases. (A) A chest CT at the start of treatment in Case 1; (B) A chest CT after 2.5 months from treatment initiation; (C) A chest CT at the start of treatment in Case 2; (D) A chest CT after 1.8 months from treatment initiation (E); A chest CT at the start of treatment in Case 3; (F) A chest CT after 1.8 months from treatment initiation.. Yellow lines indicate target lesions.
case_images: cureus-0016-00000052714-i02.jpg
case_images: PMC10880137_03_cureus-0016-00000052714-i02.jpg
case_images: FIG2
case_images: After 1.8 months from treatment initiation, chest CT revealed pneumonitis and MPM progression (Figure 1B, 2E, 2F).